Clinical Trials · NCT05328843
Study to Evaluate the Pharmacokinetic Characteristics of Pegylated Exenatide Injection (PB-119) in Subjects With Different Degrees of Renal Insufficiency and Matched Subjects With Normal Renal Function
- Phase
- Phase 1
- Recruitment status
- Unknown
- Sponsor
- PegBio Co., Ltd.
- Enrollment
- 24
- Start date
- May 2022
- Locations
- 1 site, China
- Primary endpoint
- Primary PK parameters: AUC0-inf